This revealed that a SETD2 deleterious mutation was associated with a more inflamed tumor microenvironment in patients with renal cell carcinoma (Figure S4A), colorectal adenocarcinoma (Figure S4B), and endometrial carcinoma (Figure S4C). This evidence concerns the gene SETD2 and renal cell carcinoma.